Sunshine Biopharma regains Nasdaq minimum bid price compliance

Sunshine Biopharma Inc.

Received Staff notice on Feb 9, 2023, confirming compliance with $1 bid price rule.
Regained compliance removes immediate delisting risk from Nasdaq.
Company's common stock (SBFM) and warrants (SBFMW) continue trading on Nasdaq.

item 8.01

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-000805

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.